The SmartTab offering is now closed and is no longer accepting investments.

SmartTab

Future of Drug Delivery

SmartTab

Future of Drug Delivery

Denver, CO
Health Tech
We believe SmartTab is a revolution in drug delivery for superior compliance, painless injections, and truly targeted medications. We are developing a platform of ingestible drug delivery technology that is moving through clinical studies, FDA approval process, and is targeting launch to market by 2024. This patient-driven SmartTab technology has the potential to ease the burden on patients with autoimmune diseases such as diabetes that require self-injections, providing patient-preferred delivery methods and monitoring capabilities.

$177,726

raised
97
Investors
$80M
Valuation
$4.87
Price per Share
$243.50
Min. Investment
Common
Shares Offered
Equity
Offering Type
$1.07M
Offering Max
0
Days Left

$177,726

raised
97
Investors
$80M
Valuation
$4.87
Price per Share
$243.50
Min. Investment
Common
Shares Offered
Equity
Offering Type
$1.07M
Offering Max
0
Days Left
This offering ended on May 01, 2022 and is no longer accepting investments.

Reasons to Invest

  • LARGE GLOBAL MARKET: The size of the potential market for SmartTab is significant. There were 16 billion injections administered globally last year (Source). The world’s injectable market is expected to reach $931.1 billion by 2024 (Source).

 

  • MASSIVE PATIENT DEMAND: Based on our research and focus groups, there is significant demand from patients for SmartTab’s technology. We have seen that patients want to move away from daily or weekly self-injections to an oral delivery capsule platform. SmartTab received the 2021 Patients’ Choice Award by the Autoimmune Association.


  • TRACTION AND PROGRESS: We have completed lab validation and proof-of-concept through our first successful preclinical study. We are in the process of additional studies and an FDA submission, while building out a scale-up manufacturing facility and partnering with pharmaceutical companies to commercialize specific drug products.







PROGRESS OVERVIEW


The Future Here and Now

*Images are computer generated demo versions. Product is still currently under development.


SmartTab has developed a pipeline of capsule-sized ingestibles that incorporate advanced electronics and engineering for optimal drug delivery. The company is focused on launching InjectTab™ for oral delivery of biologics.




Scientists say smart tablets could improve the effectiveness of medications



We Believe the SmartTab Platform is the Most Significant Development in the Healthcare Management System in 200 Years

Our integrative team is composed of experienced engineers, pharmaceutical R&D and regulatory experts in a world-class facility for patient-centered innovation. Combining our backgrounds from the pharmaceutical and wireless medical device industries we developed the InjectTab™, what we believe to be a revolution in oral biologic drug delivery intended to replace the needle and syringe.


*Images are computer generated demo versions. Product is still currently under development.


InjectTab™ is a microneedle capsule with sensors and a microprocessor that we hope will confirm ideal positioning of the capsule and deliver life-saving biologic medication through an oral route of administration. Not only does our platform have the potential to deliver medicine less painfully and more effectively to the human body, we can obtain superior compliance and patient outcomes. We believe our team is well positioned in the industry to lead a new era of patient-centered drug delivery with strategic partners in the pharmaceutical industry and with the regulatory expertise to bring InjectTab™ technology to market by 2024.



Our Progress for Superior Compliance and Painless Injections Is Driven by Our Patient-centered Innovation





THE PROBLEM


Self-Injection of Biologics Are Painful and Invasive

(Source)


Large scale chronic diseases (i.e. Diabetes, Crohn’s Disease, Ulcerative Colitis, Psoriasis, Rheumatoid Arthritis, Cancer) are often treated with drugs that utilize a syringe or auto-injector. These administration methods can often cause stress, pain and anxiety which leads to poor adherence.


(Source)


You or someone you know may take an injection once a week or every day. Even though medicine itself has advanced, the way medication is delivered into the human body hasn't, and we are still stabbing ourselves with the antiquated needle and syringe technology.


Healthcare is increasingly happening at home and there is a lack of real-time monitoring within the current drug delivery technologies. SmartTab will be combining precision medication delivery with the latest sensor technology to communicate in real-time.

THE SOLUTION


Novel Ingestible Drug Delivery



 *Images are computer generated demo versions. Product is still currently under development


Over the last decade, Smartphones and wearable technology have transformed the delivery of healthcare. The same thing is now happening with pharmaceutical drug delivery systems leading us into the Decade of Ingestibles.


g

g

g

*Images above are computer generated demo versions. Product is still currently under development.




THE MARKET


Anticipated Launch into the Expected $931B Global Injections Market 


(Source, Source)


There are 16 billion injections administered every year around the world. The global injectable drug delivery market is expected to reach $931.1 billion by 2024. (Source, Source) Driving this growth is an increasing demand for minimally-invasive procedures— as well as better patient monitoring and outcome capabilities.


InjetTab™ will be launched into a pipeline of drug products starting with Insulin:


(Source, Source, Source)



THE BUSINESS MODEL


Partnering with Pharma to Launch



The SmartTab business model focuses on partnerships with pharmaceutical companies, we create the device and they provide the drug. SmartTab manufactures and supplies the capsules to pharma companies who load the capsules with their active ingredients and distribute through their channels—providing the patient with optimized therapies and superior outcomes. During the development process there are milestone payments as we move toward commercialization. Once commercialized, SmartTab will be paid by the pharmaceutical companies for the smart capsules.



THE VISION


Smart Pills for Optimized Therapies



Our Founder/CEO is planning to build upon his success with startup Nano Pharmaceutical Laboratories. He has a strong background directing research and development projects in the pharmaceutical space as a visionary entrepreneur on a mission to develop advanced drug delivery systems to improve patients' lives.


*Images are computer generated demo versions. Products are still currently under development.


SmartTab plans to pursue a phased platform approach for product development and commercialization. Each configuration is expected to be developed and commercialized, beginning with InjectTab™. The next capsules in the pipeline are TargetTab™ and MultiTab™. Future applications include diagnostics, surgical capsules, advanced endoscopes, pacemakers, and more.



WHY INVEST


Clear Line of Sight to Market



We believe SmartTab is leading the digital drug delivery revolution through patient-centered innovation, diligent engineering, and powerful partnerships with pharmaceutical companies. We believe the team is on a clear path to complete additional clinical studies, obtain FDA approval and bring InjectTab™ to market by 2024. We plan to advance care delivery for the 21st century—right here, right now.





In the Press

TechCrunch

SmartTab | Disrupt 2020

FOX Tech Talk

Scientists say smart tablets could improve the effectiveness of medications

Medgadget

SmartTab Wireless Pill for Targeted Drug Delivery: Interview with CEO Robert Niichel

Denver Business Journal

Coming soon: A pill that time-releases meds and records your body data

Healthcare Goes Digital Podcast

When Wireless Technology Meets Drug Delivery

The Medical Futurist

Top100 Digital Health Companies 2021

MedStreet Journal Podcast

Developing More Accuracy in Treatments and Diagnosis Powered by Capsules and Wireless Technology with Doug Miller

American Inno

Denver Startup Develops Smart Pill for Wireless Drug Delivery

IBD Journal

Advancing High Tech Drug Delivery Systems for the Treatment of Crohn’s Disease

Offering Summary


Company

:

Velóce Corporation

Corporate Address

:

3513 Brighton Blvd. Lab 310, Denver, CO 80216

Offering Minimum

:

$9,998.11

Offering Maximum

:

$1,069,992.57

Minimum Investment Amount

(per investor)

:

$496.74











Terms


Offering Type

:

Equity

Security Name

:

Common Stock

Minimum Number of Shares Offered

:

2,053

Maximum Number of Shares Offered

:

219,711

Price per Share

:

$4.87

Pre-Money Valuation

:

$80,002,192.85











Voting Rights of Securities Sold in this Offering

Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.

Early Bird

Friends and Family - First 72 hours | 10% bonus shares

Super Early Bird - Next 72 hours | 5% bonus

Early Bird Bonus - Next 7 days | 3% bonus shares

 

Volume

Tier 1 - ($10,000+5% bonus shares)

Tier 2 - ($25,000 + 8% bonus shares)

Tier 3 - ($50,000+10% bonus shares)

*All perks occur when the offering is completed.

StartEngine Owner’s Bonus:

SmartTab will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $4.87/share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $487. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

In March 1994 Robert Niichel was barred from association with any NASD member in any capacity. Please refer to the Company’s Risk Factors for full disclosures.

The Company will not incur any irregular use of proceeds.


Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$195,400.00 USD
$1,552.00 USD
Cash And Cash Equivalents
$195,400.00 USD
$1,552.00 USD
Accounts Receivable
$0.00 USD
$0.00 USD
Short Term Debt
$50,720.00 USD
$14,581.00 USD
Long Term Debt
$0.00 USD
$0.00 USD
Revenues And Sales
$0.00 USD
$0.00 USD
Costs Of Goods Sold
$0.00 USD
$0.00 USD
Taxes Paid
$0.00 USD
$0.00 USD
Net Income
-$991,077.00 USD
-$1,101,014.00 USD

Risks

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.


Updates

Thank You! We Did It!

3 months ago


Dear SmartTab Investor Community,

Congratulations to everyone who invested during our equity crowdfunding campaign. We want to thank you for your partnership and commitment to advancing drug delivery technology.

On behalf of the entire SmartTab team, we’d like to extend our utmost gratitude and thanks to each and every one of our valued investors, supporters, friends and family. We’re absolutely thrilled by what we’ve achieved, opening up investments to individual investors and raising a total of $177,726 from 97 investors. Thank you for all the support we’ve received—from phone calls, emails, and texts. We will stay in touch along the way as we target larger strategic funding and advance SmartTab technology. Look out for our monthly investor only email updates and quarterly webinars. 

We are excited for this next chapter of SmartTab as we take our efforts to the next level to move our technology through clinical studies and FDA process.  We are on the leading edge of discovery alongside the most talented individuals in the area of wireless technology and pharmaceutical drug delivery. Thank you to our entire team for their tireless work over the years since beginning this journey, and this equity crowdfunding capital raise is a validation of our progress and determination. We are well on our way to achieving our goal of building the future of drug delivery together for patients.

We appreciate each and every one of you for believing in us and joining our journey to bring this cutting-edge technology to every patient and evolve the experience of drug delivery to one that is deserving of the 21st century.

Thank you!

Only 12 Hours Left to Invest!

3 months ago



SmartTab's equity crowdfunding campaign giving individuals an opportunity to own a stake is officially closing on StartEngine. Only 12 hours left to stake your claim in transformative drug delivery technology as this equity crowdfunding campaign is ending.

Join us on our journey to bring this cutting-edge technology to every patient and evolve the experience of drug delivery to one that is deserving of the 21st century.

Now is the time to Top-up your investment or become an investor before it is too late.

Please complete your investment by clicking the link below.

Click Here to Invest


✨ Final Hours to Invest!

3 months ago

Dear SmartTab Investor Community,

As this equity crowdfunding campaign comes to an end. We look back on all the milestones and progress we've made in the last quarter and beyond. We've come this far from concept to reality thanks to passionate investors like you. We appreciate each and every one of you for believing in us and joining  our journey to transform a significant patient need. This is the beginning of a new chapter for SmartTab as we now focus on forwarding our intellectual property, conversations with the FDA, pharmaceutical partnerships, completing InjectTab™ preclinical studies and raising large strategic funding to reach commercialization. This is a mission, we are doing this for patients and for humanity. Everyday we continue to make progress and now we accelerate our efforts to build the future of drug delivery together. 

✨ Lab Facility in Health Tech Innovation Center in Denver and Plans in Place for Expansion to Larger Manufacturing Facility

✨ InjectTab™ Gastric Environment Validation Process Completed

✨ Successful TargetTab™ Animal Study and InjectTab™ Preclinical Study Underway for Summer 2022

✨ Currently in Dialogue with FDA: Pre-Submission In-Progress

✨ Total of 3 Patents Issued, 5 Patents Pending - Most Recent Patent Issued Jan. 2022

✨ Successful Startup Health Festival @ ViVE Conference 

✨ SXSW Pitch Finalist,  CEO of SmartTab Recognized on Denver Business Journal

✨ Named Top 100 Digital Health Companies by Medical Futurist

✨ Completed PharmStars Accelerator to Advance Digital-Pharma Partnerships

You still have time to top-up your investment or become an investor before it is too late!

Visit the link below to complete your investment today.

Click Here to Invest

Intellectual Property Update: "Wireless Communications System Integrating Electronics Into Orally Ingestible Products for Controlled Release of Active Ingredients"

3 months ago

Dear SmartTab Investor Community,

With only 1 day left to invest in SmartTab on StartEngine we thought it would be great to take a deep dive into our intellectual property. We have been aggressive with our IP and already have 3 patents issued to date with 5+ currently pending. Your investment fuels our work with the best in the industry for obtaining intellectual property rights and using those rights to protect and promote SmartTab as we grow. 


"Wireless Communications System Integrating Electronics Into Orally Ingestible Products for Controlled Release of Active Ingredients"


Now is the time to top-up your investment or become an investor before it is too late. So far, we have raised $169,919 from 90 investors. We are so thankful for all of our investors so far, and look forward to the growth that would not be possible without your investment. Visit the link below to complete your investment today.

Click Here to Invest

Only 2 Days Left to Invest!

3 months ago

Dear SmartTab Investor Community,

These are the final moments to stake your claim in SmartTab's drug delivery technology. We want to thank all of you for participating and believing in our team. Join us in advancing our InjectTab technology for delivery of biologics and large molecules to create a significant shift in drug delivery. Listen in to our Founder and CEO on the Health Innovators show. Patient co-creation: How to play the long game with novel tech in healthcare w/ Robert Niichel. 


This is your final opportunity to contribute to the advancement of drug delivery systems and improving the patient lives. 

Visit the link below to complete your investment today.

Click Here to Invest

Business Update: Reducing Capsule Size

4 months ago

Dear Investor Community,

As we move into preclinical studies with InjectTab, we are reducing the capsule size from 000 to 00.

InjectTab is currently based on the 000 size capsule highlighted above but by leveraging miniaturization techniques, we believe that 00 and 0 size InjectTab capsules are viable throughout development and commercialization.

Join our investor community while you still can. ⏰ There are only 2 days left to invest in our Reg CF offering, and a minimum investment makes you eligible for the StartEngine Owner’s Bonus of 10% bonus shares. These are the hours to stake your claim in SmartTab’s transformative drug delivery technology. Visit the link below to complete your investment.

Click Here to Invest

🎥 LIVE on Startup Health TV With Only a Couple of Days Left to Invest in SmartTab!

4 months ago

Dear SmartTab Investor Community,

SmartTab, joined Startup Health in 2016, on a mission to provide patient-centered wireless precision drug delivery to every patient, in every household, in every country, bringing advanced drug delivery systems to market to optimize patient care. Watch this candid interview with Chief Marketing Officer of SmartTab LIVE on Startup Health TV during the ViVE conference. This interview covers InjectTab and the patient preferred oral method of delivery for biologics, realtime monitoring to optimize the medication delivery and the importance of bringing this technology to market. 

As we enter the final 3 days of our StartEngine raise, we want to thank each and everyone of you who invested so far. This is your opportunity to invest and hold a stake in the transformation of drug delivery technologies. Now is the time to top-up your investment or become an investor before it is too late. Please complete your investment by clicking the link below.

Click Here to Invest

4 Days Left Invest in SmartTab 🏁

4 months ago

Dear Investor Community,

SmartTab is developing inner body technology to transform how we diagnose and treat chronic disease. A pharmaceutical product line focused on improving patient adherence and outcomes, enhancing remote patient monitoring and IoMT, optimizing clinical efficacy, and patient treatment plans. 

These are the final days to stake your claim in our transformative drug delivery technology and profit when the company does well. Now is the time to top-up your investment or become an investor before it is too late. Don't miss your chance to claim your piece of ownership! Please complete your investment by clicking the link below.

Click Here to Invest


Watch the recordings of SmartTab’s investors’ webinar series. The webinar is a remarkable opportunity to get involved early and learn more about how SmartTab will transform healthcare and patients’ lives for the better.

Watch the Webinar Recordings

5 Days Left to Invest in SmartTab!

4 months ago

Dear Investor Community, 

Only 5 days left to invest in SmartTab so here are our top 5 reasons to invest: 

  • Large Global Market: The world’s injectable market is expected to reach $931.1 billion by 2024
  • World-class Team: CEO with 25+ years in Pharmaceutical R&D and CTO 30+ Years in Med Device / Pharmaceuticals
  • Preclinical Studies: Already completed one successful preclinical study moving into additional studies this Summer
  • Addressing Patient Needs: We received the Patients' Choice Award and are addressing significant needs around drug delivery. 
  • Partnership Traction: We completed PharmStars and are partnering with Pharmaceutical companies to bring this technology to market. 

Here's a video that demonstrates the InjectTab™ and the capsule functioning in the lab beaker:


The SmartTab team made a visit to our CRO for the preclinical studies last week to prepare for a PK study with the InjectTab™ this summer. SmartTab will be expanding to a larger manufacturing facility by the end of the year to build out larger quantities for upcoming clinical studies. What was once an idea is becoming a reality and we can't do it without passionate investors like you. Together we can transform the future of drug delivery and improve patient lives. Don't miss your chance to be an early investor and claim your piece of ownership! Please complete your investment by clicking the link below. 

Click Here to Invest

🚀 Offering Closing Soon—Invest in the Future of Drug Delivery!

4 months ago

Dear Investor Community,

This is the final week for individuals to invest before we move on to larger strategic funding. We are so thankful for all of our investors so far. Patients can't wait for this technology, as Patient Advisor of SmartTab speaks about below in a snippet from our webinar on Thursday. 

Now is the time to top-up your investment or to become an investor before it is too late. There are only 7 days left to invest in our Reg CF offering, and a minimum investment of just $250 makes you eligible for the StartEngine Owner’s Bonus of 10% bonus shares.  Visit the link below to complete your investment today.

Click Here to Invest

🎥 Watch Investor Webinar Recording: Addressing Patient Needs Around Drug Delivery

4 months ago

Dear SmartTab Investor Community,

Today SmartTab officially enters the final 8 days of our Reg CF offering here on StartEngine!

We want to thank all of you who attended our investor webinar yesterday morning. In this webinar, Tina Aswani Omprakash, public health advocate behind Own Your Crohn’s courageously shared her story of living with Crohn’s disease and why SmartTab presents so much hope for patients.  It was an inspiring conversation and really speaks to the importance of advancing drug delivery systems right now. The webinar concluded with a LIVE Q+A with the SmartTab team. 

The playback is now available on-demand, see the link below to watch the webinar.


Click Here to Watch the Webinar Recording

As we near the closing of our campaign, we want to thank all of our investor community for believing in us, and helping us take our vision to reality.  These are the final days to stake your claim in SmartTab’s drug delivery technology. Take advantage while you can! This is your opportunity to contribute to the advancement of drug delivery systems and improving the patient lives. Visit the link below to complete your investment today.

Click Here to Invest

⏰ Register for the Investor Webinar Starting in 30 Minutes!

4 months ago

Dear Investor Community,

Today we are going LIVE at 11:00am Mountain Time for an Investor Webinar with SmartTab's Patient Advisor, Tina Aswani Omprakash and the SmartTab team. There will be a Q+A to get all of your questions answered. There's still time to register by clicking the link below. 

Click Here to Register for the LIVE Webinar

We are in the final 9 days before this raise is gone for good. Don't miss your chance to invest in SmartTab before we move on to a larger strategic capital raise. Please complete your investment by clicking the link below.

Click Here to Invest

⚡ More on Preclinical Studies and Why Now is the Time to Invest! ⚡

4 months ago

Dear SmartTab Investor Community, 

We’re close to the end of our campaign. From everyone working at SmartTab would like to say that your support has been very important to all of us. To all the people interested in investing, here are some of the reasons why we think you should do it now:

✅ Patients can’t wait! Just check out the blog post about SmartTab by award winning blogger and patient advocate Tina Aswani Omprakash about the hope our technology provides and why it’s important that we advance these technologies into the market. 

✅ We completed one successful preclinical study to date. This was with the TargetTab™ capsule which has about 70% of the same architecture as the InjectTab™. You can find the published abstract in the IBD Journal and Journal of Gastroenterology

Here is a summary video from that successful study: 

✅ Preparations are well underway to advance InjectTab™ into preclinical studies this summer. In fact tomorrow the team will make a visit to the research facility where these trials will be conducted.  

Here is a video of the Gastric Environment Validation Process in the Lab: 


✅ We’ve obtain 3 issued patents to date with 5+ patents pending and we continue to be aggressive with our intellectual property.

✅ Our partnering conversations with pharmaceutical companies continue to progress since our participation in the PharmStars accelerator and we are in the process of securing strategic partnerships to advance this technology forward.

Many more reasons to list and we invite you register for SmartTab's LIVE Webinar happening Thursday, April 21st at 11:00am MT to learn more and get your questions answered.

⏰ There are only 10 days left to invest in our Reg CF offering, and a minimum investment of just $250 makes you eligible for the StartEngine Owner’s Bonus of 10% bonus shares. 

These are the final days to stake your claim in SmartTab’s transformative drug delivery technology. Take advantage while you can!

Click Here to Invest

Only 10 Days Left to Invest! Register for Tomorrow's Investor Webinar: Addressing Patient Needs Around Drug Delivery

4 months ago

Dear Investor Community, 

In the final days of SmartTab’s StartEngine campaign, Tina Aswani Omprakash, an award-winning blogger from Own Your Crohn’s is going to share her insight and hope for a future with drug delivery that’s more patient-centric on Thursday, April 21, 11 a.m. MST—register here. Tina will discuss the needs of people suffering from Crohn’s disease and other chronic illnesses. 


Tina will share her powerful story of living with Crohn’s disease and speak to the needs of patients in today’s healthcare system. Sacha Francois Heppell, Chief Marketing Officer of SmartTab will lead a fireside chat and an insightful Q+A session with Tina and the founders of SmartTab. Join us to get your questions answered live!

Click Here to Register for the LIVE Webinar

Our Founder and CEO, Robert Niichel, was interviewed today by Dan Kendall for the Digital Health Today Podcast. 🚨 This is it! There are only 10 days left to invest with SmartTab and claim your piece of ownership. Together we can accelerate the future of drug delivery right here, right now. Complete your investment by clicking the link below.

Click Here to Invest

Final 11 Days to Invest - SmartTab Participated at the Medtech Innovator Road Show Today!

4 months ago

Dear Investor Community,

MedTech Innovator Road Tour is where companies get invited to participate in one of a series of pitch events, awarding a coveted opportunity to meet with industry leaders. The pitch event judges include investors, providers, and senior executives from world-class medtech companies such as Johnson & Johnson, Becton Dickinson, Edwards Lifesciences, Dexcom, Olympus, Nipro, W.L. Gore and others. Historically, participation has resulted in financial investment, recruitment of board advisors, and establishment of research partnerships for startups, among other outcomes. 

We've come this far thanks to our supporters and investors like you. We’ve raised $151,234 from 78 investors to-date.  Don't miss your chance to be an early investor! Please complete your investment by clicking the link below.

Click Here to Invest

12 Days Until This Raise is Gone Forever!

4 months ago

Dear SmartTab Investor Community,

🚨 We’re coming down to the wire! There are only 12 days left to invest in the novel drug delivery technology offered by SmartTab. 



As the world’s injectable market is expected to reach $931.1 billion by 2024, the size of the potential market for SmartTab is significant. We are focused on launching InjectTab™ for oral delivery of biologics. Don't miss your chance to be an early investor! Complete your investment by clicking the link below.


Click Here to Invest

Announcing Smarttab's Investor Webinar With World-renowned Patient Advocate Tina Aswani Omprakash Focused on Addressing Patient Needs Around Drug Delivery for Final Days of Startengine Campaign

4 months ago


Dear SmartTab Investor Community, 

With only days left in our StartEngine capital raise, this is the final opportunity for individuals to own a stake in SmartTab before we move on to larger strategic funding. You are invited to join us for a LIVE Investor Webinar this Thursday that will address patient needs in drug delivery and SmartTab's new technologies to avoid patients having to go through painful injections.

Thursday, April 21st at 1pm ET / 11am MT

Whether you're a patient, caregiver, friend, potential investor or all of the above, we encourage you to join us to learn more about SmartTab and be part of the transformation of patient drug delivery systems. 

Register Here to Join Us Live for the Webinar

What if you were able to simply take a pill to get insulin?

4 months ago

Dear SmartTab Investor Community,

What if you were able to simply take a pill to receive the medication you’re used to receiving through a shot, like insulin? As a leading innovator and disruptive drug delivery company, SmartTab is driving the future of drug delivery to places people would have never expected it to go and injections with a conventional syringe and needle will soon be a thing of the past.  

*Some images are computer generated demo versions. Product is currently under development.

Now is the time to top-up your investment or become an investor before it is too late. So far, we have raised $147,544 from 73 investors. We are so thankful for all of our investors so far, and look forward to the growth that would not be possible without your investment. Visit the link below to complete your investment today.

Click Here to Invest

Notice of Funds Disbursement

4 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, SmartTab has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in SmartTab be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Join Our Next Investor Webinar Live Q+A

4 months ago

With just days left to invest in SmartTab, join us for our next Investor Webinar on Thursday, April 21st at 11:00am Mountain Time. 

  • Discover the patient need and importance of SmartTab
  • Learn about the latest updates with the InjectTab technology
  • Participate in a Live Q+A session with our team

Click here to Register


Health Transformers Live: SmartTab Discussion on the 2022 StartUp Health Festival Stage

4 months ago

SmartTab’s CMO, Sacha Francois Heppell, sat down with Startup Health at the 2022 StartUp Health Festival @ ViVE. In the interview, he gives the latest from SmartTab, strategic partnerships and how we can work together to transform the patient experience.

There is still time to make an investment in SmartTab before the Equity Crowdfunding Raise with StartEngine is over. 

We invite you to invest and join us as we transform drug delivery for the 21st century!

Click Here to Invest


Inside the Lab: Watch InjectTab™ Functioning in the Beaker

4 months ago

Dear SmartTab Investor Community, 

We recently completed a Gastric Environment Validation Process in the lab that showcases the InjectTab™ capsule functioning in a beaker. We are preparing for preclinical studies studies in the coming months. It's amazing to see what was once an idea become a reality. 


We've come this far thanks to our supporters and investors like you. We’re very happy to say we’ve raised $141,294 from 63 investors to-date! While this is a good start, we are actively seeking more investors to help us fund our efforts. Please complete your investment by clicking the link below.

Click Here to Invest

Watch the InjectTab™ in Action

4 months ago

Dear SmartTab Investor Community, 

We are laser focused on launching InjectTab™ for oral delivery of biologics, we are grateful for your trust and support. To help visualize this revolution we are bringing to the pharmaceutical industry, we prepared a video to demonstrating how the InjectTab™ works.

*Images are computer generated demo versions. Product is currently under development.

We are making great progress and can't do it alone. Crowdfunding offers an opportunity to join in SmartTab's mission to provide novel administration routes and effective therapies that improve patient lives. Currently, we are preparing for preclinical studies this Summer followed by a submission to the FDA. We anticipate bringing the first InjectTab™ to market by 2024. Be part of the journey and become a shareholder by investing below.

Click Here to Invest

SmartTab Webinar Recording and Next Live Session

4 months ago

Dear SmartTab Investor Community,

We want to thank all of you who attended our investor webinar yesterday morning. It was an insightful Q+A session with Founder/CEO, Robert Niichel and Chief Technology Officer, Douglas Miller. For those of you who didn't make it, no problem! See the recording link below. 



Here is a link to the recording in full.


We look forward to making this an ongoing series as we continue to advance our technology, strategic partnerships, clinical studies and regulatory FDA submission. We'd like to invite you to our next SmartTab Live session. There will be new updates and conversations. This event is next Thursday, April 14th at 11am MT. 


Register for SmartTab Webinar

Investor Webinar Only One Day Away 🎉

4 months ago


We are looking forward to tomorrow's investor webinar. This is the first of a series of webinar's we will be doing this month for a deep dive into the technology, team and what's next. Don't forget to register to save your spot.  If you can't make it, you can register to ensure you receive the recording. 


Click Here to Save Your Spot


Tune in April 5th, 11am Mountain Time to:

  • Meet the SmartTab team, how far we've come and where we are going.
  • Hear from SmartTab's CEO Robert Niichel on the future of drug delivery.
  • Get your questions answered in real time.


Register for the Investor Webinar


We look forward to seeing you tomorrow! 

Don’t Miss the SmartTab Investor Webinar!

4 months ago

Dear StartEngine Investor,

The SmartTab Investment Webinar will take place on 4/5 at 11am Mountain Time. Please join the SmartTab team to learn about our latest updates and get your questions answered. Click this link to RSVP and save your spot.

Enjoy your weekend and have a listen to this great podcast preview below or the full episode on HealthTech X



SmartTab Investor Webinar Tuesday, April 5th, 11:00am Mountain Time

4 months ago

Dear StartEngine Investor, 


Join SmartTab’s CTO Doug Miller and CEO Robert Niichel for the Investor Webinar happening Tuesday, April 5th at 11am MT. 



This presentation and Q+A session is a great opportunity for early and new investors to meet the team and get your questions answered. 


Register Here for the Webinar


We look forward to seeing you then! 

SmartTab CMO Honored in NYC at the MM+M Magazine 40 Under 40 Gala

5 months ago


Dear Investor, 

Our Chief Marketing Officer was honored last week in New York City by MM+M Magazine. 



“It’s no secret that, within the broader marketing world, capable and enthusiastic young leaders are in high demand. This year’s 40 Under 40 honorees will show just how many of them have gravitated toward healthcare. As a result, the industry’s future is in good hands.”  MM+M editor-in-chief Larry Dobrow.


NEW YORK, NY – MM+M awarded its newest class of 40 Under 40 honorees at the Edison Ballroom Friday, March 25th, and Sacha Francois Heppell, the Chief Marketing Officer for SmartTab, was an awardee. Broadway Star Geoffrey Kidwell emceed the event. In its third year, the program shines a light on the young marketers whose leadership, strategic thinking, and digital expertise have contributed to the industry’s continued growth at a challenging time for the healthcare industry. 



SmartTab is a revolutionary medtech startup that’s transforming wireless drug delivery. Sacha was honored along with a variety of globally recognized medical marketers including executives from Meta, Jansen, Johnson & Johnson, Bristol Myers Squib, Gilead Sciences, and more. Sacha was the only honoree from a Colorado-based company.



“It’s been a remarkable journey working and growing with SmartTab. We have accomplished so much in such a short period of time, but we are just getting warmed up. I feel honored by MM+M’s support for our work and am confident that SmartTab will continue our success to improve drug delivery for patients.” —Sacha Heppell, SmartTab CMO 


The 40 Under 40 list includes exceptional young experts hailing from an impressively wide range of employers. Everyone from pharma and biotech companies and agencies to device manufacturers, analytics firms, and health media. Honorees hold essential accounts, strategy, and creative positions. With the world of medical marketing continuing to evolve in the digital era, these incredible people inspire confidence among industry veterans that this field will continue to grow and evolve rapidly.


Check out the feature in the March issue of the MM+M Magazine. 

Learn More on MM+M


SmartTab Featured in the Denver Business Journal Health Care Section

5 months ago

Dear Investor, 

SmartTab was featured in the Denver Business Journal Health Care section today. 

Joshua Mann reporter from Denver Business Journal interviewed Robert Niichel CEO of SmartTab 

You can read the full article here or a preview below: https://www.bizjournals.com/denver/news/2022/03/28/colorado-smarttab-finalist-sxsw-pitch.html


This Colorado startup pitched at SXSW: Here's what happened

The company was the only Colorado company selected as a finalist to present at the SXSW pitch competition.


Robert Niichel is the founder and CEO of SmartTab.

By   –  Reporter, Denver Business Journal

Denver-based medical startup SmartTab was the only Colorado company selected as a finalist to present at the South by Southwest Pitch competition this month, where the company’s top executive said he was able to get the organization in front of a lot of fresh eyes.

The SmartTab team typically spends more time at medical and pharmaceutical conferences, so the broader attendee base at SXSW made for broader horizons for the company, said CEO Robert Niichel.

“Here, there was everything,” Niichel told Denver Business Journal. “What was really interesting for us was that we got to meet a lot of people outside the pharma space.”

Pharmaceutical companies tend to be large with a long history that gives them a culture of conservative business decisions, Niichel said. SmartTab’s trip to SXSW opened the team's eyes to opportunities the company might have to partner with technology companies that are closer to their entrepreneurial roots.

“A lot of companies in the tech space found what we were doing very interesting,” Niichel said. “They were new companies 20 or 30 years ago, so they still have that entrepreneurial spirit. A little more risk-taking, a little more open to new ideas.”

SmartTab, a Colorado Inno 2020 Inno on Fire honoree, is developing an ingestible drug-delivery system that would inject medication internally. Niichel had always thought of a pharmaceutical company as the ideal strategic partner, but he’s now seeing potential to work with technology companies.

Read More on Denver Business Journal

SmartTab Shines a Light on Novel Drug Delivery at SXSW Pitch 2022

5 months ago


SmartTab was a finalist in the Health, Wearables & Wellbeing category for the 14th annual SXSW Pitch.


Group photo of all the 2022 finalists during the award ceremony.

The team arrived in Austin on March 11th, kicking off with rehearsals for the big pitch that took place the following day. Robert Niichel, Founder and CEO of SmartTab presented to a live audience of investors, strategic partners and conference attendees. Sacha Francois Heppell, Chief Marketing Officer of SmartTab controlled the slides while Robert took the stage and charismatically shared about the InjectTab™ oral biologic delivery capsule. The presentation was three minutes and included a six-minute Q+A interaction with the judges. 

The judges included industry moguls like Stacy Feld (Johnson & Johnson), Lance Armstrong (Next Ventures), and more. Each judge had an opportunity to ask questions during the Q+A. This year’s event featured 45 of the most innovative and cutting-edge technology companies competing in nine categories before panels of industry experts, high-profile media professionals, and representatives from the Venture Capitalist and Angel communities.


SmartTab team getting ready to pitch at SXSW 2022.

The global conference and festivals celebrate the convergence of tech, film, music, education, and culture. SXSW Pitch is the marquee event of South by Southwest® (SXSW®) Conference & Festivals Startups Track, where leading startups from around the world showcase some of the most impressive technology innovations. Out of the 655 companies that applied to present at SXSW Pitch 2022, SmartTab was selected among the 45 finalists. Below is a recap video with highlights of SmartTab's pitch. 


Recap video of SmartTab at SXSW 2022.

“We were thrilled to be present InjectTab™ at SXSW and we are honored to be the only Colorado startup selected as a finalist for the pitch. This is a win for people with chronic health conditions and the future of patient-centered drug delivery systems.”

—Robert Niichel, Founder & CEO, SmartTab

Robert Niichel, CEO of SmartTab at the Inc. Founders lounge.

Following the SXSW Pitch, Robert Niichel headed to the Inc. Magazine Founders lounge to meet and network with the editors of the magazine and fellow founders. Robert is a successful founder who often shares advice to other founders on fundraising, leadership, and business growth. The Inc. Founders house included educational sessions and networking events for founders only.


Interview on Founders Suite "Teddy Talks" about fundraising.

Robert Niichel, CEO of SmartTab was interviewed during the event for a founders-focused tv series sharing fundraising advice. Robert was interviewed for the famous "Teddy" Talks that travel the world interviewing founders sharing their best advice. The interview took place on the rooftop with the downtown Austin skyline in the backdrop. 

Following the interview, it was now time for the awards ceremony, which was hosted by Mandela Schumacher-Hodge Dixon, Founder and CEO of Founder Gym, and Clyde Hutchinson, General Partner of Team ABC, a global venture capital firm. Sonavi Labs was the winner of the Health, Wellbeing & Wearables category, the company uses AI to create a telehealth system to improve patient outcomes by diagnosing and remotely managing respiratory diseases. SmartTab was proud to be a finalist in this years' competition, congratulations to all the winners, participants, and judges from the SXSW Pitch.

According to SXSW, previous pitch finalists from 2009 to 2021 have proven to be successful in the global startup ecosystem:

  • 82% received funding
  • Some received in excess of almost $14.5 billion in funding
  • 17% were acquired by companies such as Google, British Telecom, Huffington Post, Apple, Live Nation, OpenTable, Constant Contact, and Harmon


Meet the finalists demo day, Robert Niichel, CEO of SmartTab showcases InjectTab™ prototype.

The following day was the "Meet the Finalists Day." This was an opportunity to meet one-on-one with the 45 finalists. For SXSW attendees, tech investors, influencers and media, this event is the perfect time to discover what inventive minds are creating in new technology that will change the world. SmartTab showcased prototypes and made excellent contacts during the day.

Ultimately, the SXSW Pitch and Conference was a great opportunity to meet new strategic partners and spread the word about the novel drug delivery technology SmartTab is pioneering. As InjectTab™ moves further down the road to commercialization more and more people are taking note of this technology and the difference it can make in patients' lives. 

Startup Health Festival at ViVE Recap

5 months ago


Dear Investor,

SmartTab had a successful conference with the Startup Health Festival at ViVE in Miami Beach.

The SmartTab team was interviewed for Startup Health TV—and on the Startup Health stage over the four days highlighting SmartTab’s story and the latest progress of the InjectTab™ oral biologic delivery capsule. In addition to the precedent-setting presentation, SmartTab met with key investors and Pharma partners to advance clinical studies, regulatory, and pre-market commercialization activities.


FNWZoMeXoAM3glz


The conference was an opportunity for connecting with the movers and shakers of healthcare. Executives from Samsung to Amazon Care, Amazon Pharmacy, CVS Health, and additional digital health-focused pharmaceutical companies such as Takeda, Roivant, and Teva. It strengthened SmartTabs current and potential partnerships while bringing exposure to the industry of the new wave of drug delivery.

“We are bringing to market InjectTab™, to replace the syringe and needle for oral delivery of biologic pharmaceutical products.”

-Sacha Francois Heppell, Chief Marketing Officer, SmartTab

An audience of C-suite executives, senior digital health leaders and buyers, health startups and investors, government and solution providers gathered to listen to SmartTab speak with fellow Startup Health companies on a mission to transform the health and well-being of everyone on the planet. Watch Startup Health’s premier, an inspiring documentary about the transformation of healthcare.

 


SmartTab is a portfolio company part of Startup Health when it first started about 4 years ago. Being part of the Startup Health cohort is raising awareness about SmartTab and provides industry connections to investors and strategic partners. On the Startup Health stage, when asked what SmartTab sees for the next five years Sacha said,

“There are 16 Billion injections administered globally every year, SmartTab is one of the few companies that has strong potential to touch every person in the world. Five years from now we anticipate SmartTab technology being utilized in every prescription drug product for biologics and other prescription drugs.”

-Sacha Francois Heppell, Chief Marketing Officer said on the Health Transformer Stage.

Bringing wireless technology to pharmaceutical capsule-formed drug delivery would revolution medications for the 21st century. This game-changing technology is a patient-preferred route of administration for medical therapies. While breaking the barriers to adherence for patients who self-inject, the team expects this technology will be utilized in many drug products' evolution. 

Adherence rates for biologic medications are at an all-time low for patients suffering chronic conditions and autoimmune diseases such as Crohn’s disease, Colitis, and Rheumatoid arthritis. SmartTab is taking a patient-centered approach in the development of these novel drug delivery systems to track and optimize the medication. 

Ushering in an era of patient care that provides real-time feedback to physicians and AI systems—the company will be completing a preclinical animal study this summer for its revolutionary InjectTab™ platform.

ViVE 2022 Kicks Off and SmartTab Featured on Startup Health TV

5 months ago

Dear Investor, 

We are hitting the ground running at ViVE 2022! 

Startup Health Festival featured SmartTab in TV interview with Chief Marketing Officer, Sacha Francois Heppell about SmartTab's ingestible capsule platform technology – bringing advanced drug delivery systems to market to optimize patient care.


Tomorrow we will be live on the Health Transformer stage sharing SmartTab's story and progress at 1:30pm ET!



SmartTab Receives Acceptance Confirmation from FDA for Pre-Submission Review

5 months ago


Dear Investor, 

This week, the company has reached a major milestone regarding SmartTab's regulatory pathway upon successfully filing a Pre-Submission Package for InjectTab™ and receiving acceptance confirmation from the FDA for review. Big thank you to our Engineering and Regulatory Affairs team for making this possible. 

The purpose of the Pre-Submission is to build relationships and understanding with the FDA and educate the review team on the novel technology of InjectTab™, including design, testing and development plans that will facilitate FDA review, guide product development and application preparation. 

SmartTab will work interactively with FDA reviewers during the Pre-Submission process through meeting scheduling, administrative questions, and providing clarification on aspects of the InjectTab™ Pre-Submission documents for reviewers to respond with their best advice. We believe this is a mechanism that will foster collaboration and dialogue with the FDA to advance device development and result in a better quality submission. 


Thank you,

Robert

Founder//CEO

StartUp Health Festival @ ViVE 2022

5 months ago


Dear Investor, 

This time next week SmartTab's team will be together with senior digital health leaders advancing healthcare in Miami Beach. Sacha Francois Heppell, Chief Marketing Officer of SmartTab, will be speaking on the StartUp Health stage at 1:30 PM — 2:00 PM EST on Tuesday, March 8th sharing the latest progress of the InjectTab™ oral biologic delivery capsule. The conversation will be led by Bari Krein, JD, LLM, Chief Strategy Officer of StartUp Health.  Over the four days, SmartTab will be featured in the Startup Health Studio for a TV interview. 

Press Release: SmartTab Presents in the Startup Health Festival at ViVE Miami




SmartTab has participated in the Startup Health Festival since the beginning. The StartUp Health Festival has gathered thousands of CEOs, investors, world leaders and entrepreneurs to focus on solving the world’s biggest health challenges. Below is a clip of Robert Niichel, Founder and CEO of SmartTab presenting at the Startup Health Festival at J.P. Morgan Conference in 2018. Listen in to Robert's presentation and his unwavering stand to bring this technology to market. 


NOTE: The content in this video is from 2018 and SmartTab has made significant progress since then. 



SmartTab has come far since this time, having completed lab validation and proof-of-concept through our first successful preclinical study. We are now in the process of additional studies and an FDA submission, while building out a scale-up manufacturing facility and partnering with pharmaceutical companies to commercialize specific products. We believe the team is on a clear path to bring InjectTab™ to market by 2024. Join us on our mission to advance care delivery for the 21st century—right here, right now. 

Notice of Material Change in Offering

6 months ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the SmartTab offering. Here's an excerpt describing the specifics of the change:


Issuer is extending campaign to 4/30/22 and is lowering the minimum investment amount.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

SmartTab to Present at Startup Health Festival ViVE Conference in Miami

6 months ago

SmartTab will attend and present at the StartUp Health Festival taking place alongside the industry’s new health information technology event, ViVE, from March 6-9, 2022. ViVE is bringing together C-suite executives, senior digital health leaders and buyers, health startups and investors, government and solution providers to advance healthcare. SmartTab will present on the Health Transformer Stage among the top startups focused on solving the world’s biggest health challenges. 

SmartTab will be interviewed for Startup Health TV and on the Startup Health stage over the four days. Sacha Francois Heppell, Chief Marketing Officer of SmartTab will be speaking on Tuesday, March 8, 1-2pm highlighting SmartTab’s story and the latest progress of the InjectTab™ oral biologic delivery capsule. The conference will rally a global army of Health Transformers™ who are reimagining the future of health. One-to-one meetings will take place with investors and pharmaceutical partners.

Learn More 

SmartTab Featured on Colorado's Morning Show "It's No Bitter Pill"

6 months ago


We are excited to be featured on Colorado's morning show today!  This story covers the great work our team is up to and the drug delivery technology we will be bringing to market. Tune in and get a sneak peak into the SmartTab lab.

Watch Now


From Lab to Launch Podcast: Changing the Game for Drug Delivery with Robert Niichel, CEO of SmartTab

6 months ago


Robert Niichel the CEO of SmartTab, was featured on "From Lab to Launch" podcast on the topic of changing the game for drug delivery. What Uber/GPS is for people delivery, SmartTab is for drug delivery. Robert shares how the SmartTab team is combining wireless tech and biologics to make targeted drug delivery possible. He shares the applications of this new tech, quality controls and advice for other founders in the life sciences community. Listen in to stay up to date.

Listen on Apple , Listen on Spotify , Listen on Google


Quotes Highlights


"That's where we start, how can we make lives better for patients? And then working back from there. Now we need a capsule that will have these types of characteristics. Then we've moved backwards from that to how do we develop it? How often do you have to take it? What types of drugs can be used? And from there we really move forward in focusing on how this can make a better outcome for patients."
 
-Robert Niichel, Founder//CEO of SmartTab


"This is truly a mission, we've had prior successes and we've done some really cool things in the past and this is a mission to get it to market. To make sure this is successful, to do something that really changes patient outcomes for the better. And we're willing to put the time in to do that. So from that perspective, it's very exciting that we can work on something that will have a huge impact on virtually billions and billions of people once this is in the market."

-Robert Niichel, Founder//CEO of SmartTab 

TV News Anchor Visits the SmartTab Lab

6 months ago

We had the pleasure of welcoming news anchor Chris Parente to the lab. Here are some photos from his visit and our team hard at work in the lab. SmartTab is on the leading edge of discovery with the most talented individuals in the area of wireless technology and pharmaceutical drug delivery. We are dedicated to advancing patient-centered drug delivery systems that will  revolutionize treatment outcomes to push the boundaries of what's possible for medicine and make a tremendous difference in the process.  



Sacha Heppell of SmartTab Named by MM+M’s 40 Under 40 List As Medical Marketing Young Star

6 months ago

NEW YORK, NY – MM+M has announced its newest class of 40 Under 40 honorees. In its third year, the program shines a light on the young marketers whose leadership, strategic thinking and digital facility have contributed to the industry’s continued growth at a challenging time for the healthcare business as a whole. 

Sacha Heppell is the Chief Marketing Officer of SmartTab, a revolutionary digital medicine startup that’s transforming wireless drug delivery.

He was the only Coloradan to make the MM+M 40 Under 40 list. SmartTab has quickly grown in recent years thanks to international partnerships and a grant from the Colorado Office of Economic Development and International Trade (OEDIT).

“It’s been a remarkable journey working and growing with SmartTab. We have accomplished so much in such a short period of time, but we are just getting warmed up. I feel honored by MM+M’s support for our work and am confident that SmartTab will continue our success to improve drug delivery for patients.” —Sacha Heppell, SmartTab CMO 

The 40 Under 40 list includes individuals who hail from a range of employers, from pharma and biotech companies and agencies to device manufacturers, analytics firms and health media. At those organizations, the honorees hold a range of essential account, strategy and creative positions. With the world of medical marketing continuing to evolve in the digital era, these individuals inspire confidence that the industry is in good hands for the years ahead. 

SmartTab partnered with pharma to propel its network globally and just presented at the Arab Health 2022 Conference in Dubai. 

“It’s no secret that, within the broader marketing world, capable and enthusiastic young leaders are in high demand. This year’s 40 Under 40 honorees will show just how many of them have gravitated toward healthcare. As a result, the industry’s future is in good hands.”  MM+M editor-in-chief Larry Dobrow.

This year’s 40 Under 40 honorees hail from a range of the industry’s biggest and most well-respected organizations, including Meta, Fishawack Health, Johnson & Johnson, Weber Shandwick, & AstraZeneca. 

The 2022 class of MM+M’s 40 Under 40 will be celebrated at a dinner to be held at The Edison Ballroom in New York City on March 24. For more information about MM+M’s 40 Under 40 program, visit www.mmm40under40.com

About SmartTab

Veloce Corporation (dba “SmartTab” or the “Company”) is currently engaged in the design, development and validation of next generation ingestible capsule drug delivery systems. Based in Denver, Colorado, it operates from their world-class innovation center for patient-centered delivery systems in various stages of clinical trials and FDA submission.

About MM+M 

First published in 1966 as Medical Marketing and Media, MM+M is the media brand of record for pharmaceutical marketing and commercialization, delivering the most balanced and relevant coverage of the growing industry. The title produces an essential mix of online breaking news and analysis combined with monthly print features — timely, objective, original editorial content for an executive audience of leaders and thinkers who work in pharma, medical device, diagnostics and greater healthcare marketing. MM+M also develops conferences and live and virtual events, and engineers the industry’s premier awards program, the MM+M Awards.


VIDEO: Visit SmartTab at Arab Health 2022

7 months ago

The SmartTab team is showcasing their innovative technology at Arab Health 2022 this week. This is the one of the world's largest conferences showcasing the latest innovations in healthcare. SmartTab presented last year during the annual Arab Health Innov8 Talks on "Advancing Wireless Ingestible Drug Delivery Technologies" and today the team has a booth in the US Pavillion along side some of the most innovative health tech companies in Colorado. Watch this video for a sneak peak into SmartTab's booth.


SmartTab Selected As Finalist for 2022 SXSW Pitch

7 months ago

SmartTab to showcase InjectTab™ in the category: Health, Wearables, & Wellbeing

DENVER, CO —January 19, 2022—SmartTab, a startup that’s pioneering wireless drug delivery, was selected as a finalist in the Health, Wearables, & Wellbeing category for the 14th annual SXSW Pitch® (formerly SXSW Accelerator).

SXSW Pitch is the marquee event of South by Southwest® (SXSW®) Conference & Festivals (March 11 - 20, 2022) Startups Track, where leading startups from around the world showcase some of the most impressive technology innovations to a panel of hand-picked judges and a live audience. Out of the 655 companies that applied to present at SXSW Pitch 2022, SmartTab was selected among the 50 finalists spanning 10 separate categories.

The two-day event will be held the first weekend of SXSW Conference & Festivals, Saturday, March 12 and Sunday, March 13, on the fourth floor of the Downtown Hilton Austin, Salon D/E. The event will then culminate with the 2022 SXSW Pitch Awards Ceremony on Sunday evening, March 13, where winning startups from each category and a Best in Show winner will be announced and honored.

SXSW Pitch will feature finalists across the following nine categories: Artificial Intelligence, Robotics & Voice, Enterprise & Smart Data, Entertainment, Gaming & Content, Extended Reality & Immersive Technology, Future of Work, Health, Wearables & Wellbeing, Innovative World Technologies, Smart Cities, Transportation & Logistics, and Social & Culture.

SmartTab will present among four other companies in the Health, Wearables & Wellbeing category on March 12, 2022.

“We are thrilled to be presenting at the SXSW and honored to be the only Colorado startup selected. This is not only a great opportunity for us, but also the people that suffer from chronic health conditions that we look forward to helping with SmartTab’s products.”  — Robert Niichel, Founder & CEO, SmartTab

“Since its beginning, SXSW Pitch has significantly helped shape the early-stage venture ecosystem and connected promising companies with the resources they need to thrive, giving promising companies the resources they need to succeed when it matters most,” said SXSW Pitch Event Producer Chris Valentine. “Of the 572 companies who have participated since the competition’s inception, over 82 percent have gone on to secure funding and 17 percent have been acquired by the likes Google, British Telecom, Huffington Post, Apple, Live Nation, OpenTable. We’re excited to see this year’s impressive group of startups take to the stage and show us how their innovations will change the world.”

For more information about SXSW Pitch and to view the complete list of finalists, visit: https://www.sxsw.com/pitch.

About SmartTab

Veloce Corporation (dba “SmartTab” or the “Company”) is currently engaged in the design, development and validation of next generation ingestible capsule drug delivery systems. Based in Denver, Colorado, it operates from their world-class innovation center for patient-centered delivery systems in various stages of clinical trials and FDA submission.

About SXSW

SXSW dedicates itself to helping creative people achieve their goals. Founded in 1987 in Austin, Texas, SXSW is best known for its conference and festivals that celebrate the convergence of tech, film, music, education, and culture. An essential destination for global professionals, the annual March event features sessions, music and comedy showcases, film screenings, exhibitions, professional development and a variety of networking opportunities. SXSW proves that the most unexpected discoveries happen when diverse topics and people come together. SXSW 2022 will take place March 11 - 20, 2022. For more information, please visit sxsw.com. To register for the event, please visit sxsw.com/attend.



Finalists Announced for the 2022 SXSW Pitch Startup Event

7 months ago

SmartTab was announced as one of the finalists for South by Southwest's 14th annual Pitch event in March 2022. SXSW Pitch showcases technology from 45 companies within 9 distinct categories to a panel of industry experts, media professionals, venture capital and angel investors. SmartTab will present to a live audience of high-profile media, venture capital investors, and a panel of expert judges. This season’s judges include industry moguls like Jim Breyer (Breyer Capital), Stacy Feld (Johnson & Johnson), Lance Armstrong (Next Ventures), Deena Shakir (Lux Capital), former Walmart CEO Marc Lore, and more.  This year's finalists represent the most cutting-edge technologies from around the world, with the highest caliber of applicants since SXSW Pitch's beginning.

Full press release from SXSW here.


SmartTab Reaches Crucial Milestone with New Patent Granted by USPTO

7 months ago


DENVER—The Denver-based startup, SmartTab, continues to revolutionize digital medicine—they successfully obtained a patent for a “wireless communications system integrating electronics into orally ingestible products for controlled release of active ingredients.”

Smart Pills for Optimized Drug Delivery

This is yet another major stepping stone for the startup. Over the past three years they’ve quickly made a name for themselves as a leading innovator in wireless drug delivery systems. The company is engaged in the validation of InjectTab™ to replace the needle and syringe for patients with diabetes and autoimmune diseases. Their additional products, TargetTab™ and MultiTab™ have the potential to transform the lives of people suffering from chronic gastrointestinal problems like Crohn's disease.

To maximize medications’ effectiveness and minimize side effects, the drug needs to be targeted to the correct location and at the right time. Modern enteric-coated capsules have advanced oral drug delivery by enabling drugs to dissolve after they have bypassed the acidic stomach environment, yet even these capsules can not travel deep into the colon or  offer an indication of whether or not the drug was successfully released at the target location. 

Patent Details

The patent (U.S. Patent No. 11224383) has SmartTab poised for clinical studies in May. It entails a consumable capsule with a triaxial coil and electronic circuit which interacts with an external device so that the external device can determine the location of the capsule within the gastrointestinal tract. This system of consumable capsule and external tracking and control device delivers a pharmaceutical agent to a predetermined location in the gastrointestinal tract. The capsule electronics can present a signal indicating release of the pharmaceutical agent. Read the full announcement here.


“The new patent issued and the soon-to-be-issued patents demonstrate our commitment to advancing a paradigm shift in patient-centered drug delivery."

-Robert Niichel, Chief Executive Officer of SmartTab.

Coming Up

SmartTab is presenting at the Annual Arab Health 2022 Conference 24-27 January 2022 at Dubai World Trade Centre—showcasing Colorado’s expertise in novel drug delivery systems to the Middle East and international communities. 

Notice of Material Change in Offering

7 months ago

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the SmartTab offering. Here's an excerpt describing the specifics of the change:


Issuer is extending campaign for up to 30 days.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

SmartTab to Participate in the Arab Health 2022 Conference in Dubai

7 months ago

Denver, CO Jan. 12: A Denver-based digital health startup, SmartTab, will present at the Annual Arab Health 2022 Conference 24 - 27 January 2022 at Dubai World Trade Centre—showcasing Colorado’s expertise in novel drug delivery systems to the Middle East and international communities. 

In partnership with a Life Science delegation, the Colorado Office of Economic Development and International Trade (OEDIT) selected SmartTab to join Arab Health as an emerging health technology company. This is the largest healthcare event in the Middle Eastern and North African (MENA) region. Over 4,000 exhibitors and 50,000 visitors are expected at the trade show. 

The Annual Arab Health 2022 Conference will showcase a rich variety of healthcare innovation—ranging from state-of-the-art imaging equipment to the most cost-effective disposables; developments in surgery to advances in prosthetics. 

OEDIT provides financial assistance for companies entering new global markets through the State Trade Expansion Program (STEP). 

SmartTab presented last year during the annual Arab Health Innov8 Talks on May 31st, 2021, titled "Advancing Wireless Ingestible Drug Delivery Technologies." The company presented its drug delivery platform, the InjectTab™, TargetTab™, and MultiTab™, to a panel of judges, investors, and executives for global health companies like Philips and GE Healthcare. 

In 2022, SmartTab will host a booth in the US Pavilion as well as meet and present to potential partners and investors during the conference. SmartTab will pursue exporting and manufacturing opportunities for when commercialization is reached.

“We are proud to represent SmartTab on the global stage to share about our global wireless drug delivery revolution. This is one of the world’s largest medical conferences, and we look forward to connecting with potential partners.” -Robert Niichel, Founder and CEO, SmartTab

Notice of Funds Disbursement

7 months ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, SmartTab has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in SmartTab be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

2021 SmartTab Year in Review Podcast Episode

7 months ago


2021 Recap Podcast Episode

It's been an extraordinary year at SmartTab. Listen to the 2021 Year In Review Podcast Episode, as our CEO and CMO recap SmartTab's progress in 2021. Use the chapters to navigate the episode and explore the extraordinary accomplishments of the year.

We wish you and your family a happy new year. Breakthrough 2022!

Listen to the Full Episode


News List


We started the year at the Crohn’s and Colitis Congress presenting our Successful PK Preclinical Animal Study of TargetTab™, colon-targeted delivery system. 

SmartTab won the poster of distinction for the Preclinical Animal Model Category and our abstract was published in the the IBD Journal and Journal of Gastroenterology. 

SmartTab joined the Blackstone Entrepreneurs Network, Denver Scale-Up Program designed by the Office of Economic Development & Opportunity in Denver, Colorado 

A virtual trip to Japan to pitch at the Born Global Town Hall & Forum, a  Digital Health Event organized by Astoria Consulting Group in Japan, in cooperation with Pfizer & Japan’s External Trade Organization.

We then dived into the story of how SmartTab started, the famous bike ride that launched SmartTab and Robert Niichel as the “Godfather of wireless drug delivery” 

SmartTab Announces New Patent Granted by USPTO for its Novel Drug Delivery Systems

SmartTab team presents lecture on Advancing High Tech Drug Delivery Systems to Healthcare Engineering students and faculty of Texas Tech University led by Chief Technology Officer, Dr. Douglas Miller.

SmartTab featured on Healthcare Goes Digital podcast about the personalized aspect of wireless drug delivery.

SmartTab Rallies to Support Take Steps Colorado for Crohn’s and Colitis Foundation and Completed Patient-Centered Innovation Focus Group

SmartTab participated in a Boulder Startup Week panel about digital therapeutics. 

Our Chief Technology Officer, sat down with Jordan Hogan on Fox News Tech Talk to share about each capsule device we have in our pipeline and how it works. 

SmartTab was selected this year to pitch at the Plug and Play Health Tech Pitch. Plug and Play brings together the best startups and the world’s largest corporations to partner.

In honor of World IBD Day, Chief Technology Officer, Dr. Douglas Miller, sat down with Medical Device & Diagnostic Industry to share how we are working to change the game for diagnosing and treating Inflammatory Bowel Disease (IBD) with our ingestible technologies.

Arab Health invited SmartTab to speak during the Innov8 Talks. I had the pleasure of presenting SmartTab and sharing our innovations with the global community at the world’s largest healthcare conference. 

MedCity INVEST brings together regional and national stakeholders across hospitals, insurers, pharma, health IT, and medtech to discuss new developments in precision medicine, the reality on the ground, and what needs to happen for more widespread adoption and integration of these innovative technologies.

SmartTab was selected as a finalist and ultimately a winner of the Colorado Companies to Watch 2021 Awards. 

Reimagining Healthcare Podcast:  The smart biosensing tablet revolution enabling personalized healthcare with Robert Niichel, CEO of SmartTab

SmartTab was featured on the Health Innovators Show with Dr. Roxie Mooney about how to play the long game novel tech in healthcare

Wistia featured SmartTab's podcast as one of the top five on the platform and Chief Marketing Officer joined a webinar to share about how SmartTab’s podcast has naturally supported the growth of our company. 

SmartTab was honored to be part of Tech Delegation to London Tech Week led by London and Partners and the City of Denver Office of Economic Development. 

SmartTab partnered with General Assembly in speaking with fellow thought leaders in healthcare to explore new intersections between health and technology.

MedStreet Journal Podcast: Developing Accuracy in Treatments and Diagnosis Powered by Capsules and Wireless Technology with Dr. Douglas Miller, CTO of SmartTab

For the second year in a row, SmartTab participated in the annual TechCrunch Disrupt Conference. In 2020 SmartTab was a TechCrunch Top Pick at the Disrupt conference.

SmartTab was added to the Top 100 Digital Health Companies to Watch List by the Medical Futurist. 

SmartTab hosted a networking event at the Catalyst Health Tech Innovation Center during Denver Startup Week and Presented at the Innovative Product Showcase.

The first ever Patients' Choice Award: Health Tech Pitch Competition sponsored by Lilly, brought together the best and the brightest health tech, digital health, diagnostics and medical device startups innovating to disrupt the autoimmune experience.

SmartTab officially opened up investments to the public to accelerate the commercialization of our novel drug delivery platform. This is a new approach to fundraising that opens up more impactful investments from our greater community of investors at-large. 

SmartTab joins PharmStars,  is the first of its kind accelerator led by successful Digital Health Pharmaceutical Executives to advance Digital-Pharma partnerships.

It's with great pleasure that we announce SmartTab's Founder and CEO, Robert Niichel as the Most Innovative CEO of the Year 2021 by Tycoon Success. This is the story of an innovator who goes beyond the ordinary to accomplish the extraordinary. 

Robert Niichel Named Most Innovative CEO of the Year by Tycoon Success

7 months ago

Robert Niichel: An Innovator in the Digital Pharma Industry / A Tycoon Revolutionising the Digital Pharma Industry / Working With Really Great People

It's with great pleasure that we announce SmartTab's Founder and CEO, Robert Niichel as the Most Innovative CEO of the Year 2021 by Tycoon Success. We are proud of the hard work and leadership Robert brings to the laboratory and team. Below is the article from Tycoon Success about Robert's journey through this year and what you can expect from SmartTab going forward. This is the story of an innovator who goes beyond the ordinary to accomplish the extraordinary.

Read the Full Article

SmartTab’s Journey to PharmStars

8 months ago

A Startup’s Journey to PharmStars

The Long and Winding Road to Successful Pharma-Digital Partnerships


Photo courtesy of PharmStars

Let’s Go to the Moon, They Said…

On Sept 12, 1962, President John F. Kennedy said, “We choose to go to the moon in this decade and do the other things, not because they are easy, but because they are hard.” People couldn’t comprehend how that was possible. Yet on July 20, 1969, Neil Armstrong made the impossible, possible. As innovators that work in the startup world, we share this same passion and drive.

The moon landing is one of the best case studies of breaking through perceived barriers to boldly advance technology that didn’t seem plausible. President JFK’s leadership pushed people to accept such a daunting challenge. Today, we have the vision to fearlessly go into the unknown as well with a focused entrepreneurial spirit to create ideas that will change the world.

Gap

Photo courtesy of SmartTab

The Biggest Chasm Between Pharma and Innovative Startups

Digital health has the potential to really transform the pharmaceutical industry and patient experiences. Partnerships are essential to success when it comes to overcoming the Pharma-Startup gap.

If Big Pharma is from Mars and digital health startups from Venus, PharmStars wants to play Cupid

So how do you get innovation and digital health startups into the fold at pharmaceutical companies? It’s a burning question that hasn’t been answered. Grounded in R&D, many pharmaceutical companies do not have engineers and look to external partnerships to bring in the digital piece. There’s huge potential for “beyond the pill solutions,” but it's very difficult.

PharmStars is a new kind of accelerator for companies developing digital solutions for pharmaceutical companies. It’s the only pharma-focused, member-based accelerator for digital health startups. The goal of PharmStars is to bridge the "pharma-startup gap" by preparing both pharma and digital health startups to effectively work together.

Pharma and startups have a lot to offer each other. What's going wrong?

Both sides, Pharma and Startup must listen to each other more closely while learning to share their needs and solutions. PharmStars is creating opportunities for more conversations between Pharma and Startups to facilitate and accelerate successful partnerships.

SmartTab experienced PharmStars firsthand as a graduate of the first cohort. Let's dive into the PharmStars accelerator and discover the benefits of the bridge.

Bob (1)

Photo courtesy of PharmStars

PharmStars Helps SmartTab Boost Pharma Partnerships

Over the past centuries, both technology and medicine have rapidly advanced. Yet the way medicines are delivered to the human body remain quite antiquated. Even as pharmaceutical companies work on innovation, there is very little progress in this field.

Robert Niichel is the founder of SmartTab with a background in research and development of pharmaceutical types of drug delivery systems. Niichel has a track record of developing novel ways to increase absorption and time-release medications. In 2017 he made a choice that could very well lead to the most significant advancement in healthcare in the last 200 years. He chose to bring the advancements of wireless technology into drug delivery to improve the way active ingredients are delivered and monitored in the human body. He started SmartTab, a company dedicated to people and advancing high-tech drug delivery technology.

SmartTab is developing novel drug delivery technologies to usher in a new era of medication delivery and management. Imagine a world where advanced “smart pills” or “digital pills” not only deliver medication but also collect key data analyzed by AI systems and physicians to improve therapies and patient outcomes.

There are many challenges along the way that SmartTab will face as we build a revolutionary product to change a system (needle and syringe) that is not keeping up with the needs of patients. The team at SmartTab accepts these challenges and is dedicated to their mission. It’s important for SmartTab to partner with pharmaceutical companies as this is the pathway to pair active ingredients with our capsules and move through clinical studies as well as the FDA regulatory process.

Partnerships will be key to accomplishing the bold mission of transforming pharmaceutical delivery with digital technology. SmartTab was part of the first class of PharmStars graduates—partnering with Pharma to focus on specific therapeutic areas so that our capsules can be utilized for diabetes, IBD, mental health, cancer, covid-19, and a multitude of autoimmune diseases. 

 

GroupPhoto (1)

Photo courtesy of PharmStars

Bridging the Startup-Pharma Gap Through PharmStars

In August 2021, SmartTab and 11 other startups were selected by PharmStars to participate in the accelerator that culminated in a showcase in Boston, MA to pitch to PharmStars’ Pharmaceutical member companies. Given the need for “beyond the pill” digital health solutions and the agility of a startup to develop innovative solutions, it was a no brainer for SmartTab to embark on this new opportunity for conversation and partnering.

PharmStars was founded by Naomi Fried, who has lead technology innovation at Biogen, Boston Children’s Hospital, and Kaiser Permanente. She heads the PharmStars team which includes, former pharmaceutical executive, Laura Gunn; startup genius Dr. Shwaren Patel, and master logistics implementer, Meredith Cohen. They believe startups can benefit from better understanding the business concerns that drive pharma’s decision making. PharmStars seeks to educate and assist both their startups and pharmaceutical members to more effectively partner and ultimately move the needle in patient care. The accelerator had three components: classes and mentoring for startups, and “Executive Ed” for pharma.

The SmartTab team has already been in conversation with many of the large pharmaceutical companies throughout the world yet only few of those conversations ever led to actual collaboration on a specific development project. SmartTab was eager to accelerate those efforts and take their conversations with potential pharma partners to the next level.

PharmStars is opening up a new chapter for Pharma-Startup partnering. The 10-week program was a bootcamp for digital health startups to dive into and learn about the world of large multinational pharmaceutical companies. The startups that participated in the accelerator remained confidential for several weeks after completion to respect the Pharma-Startup member conversations.

Each week startups came together for PharmaU, PharmStars’ educational program led by Managing Director, Laura Gunn to educate the startups on how pharmaceutical companies are structured and how their products are developed. The cohort of startups met twice a week for two hours.

Naomi Fried led “fireside chats” with Pharma member Digital Health Executives who shared authentically about the challenges they face in partnering and what their team is looking for in a digital health startup partner. These discussions help guide the startups in understanding how to meet the needs of pharma.

The theme for this initial cohort was “innovation in clinical trials.” Each startup had the opportunity to present their solution at PharmStars’ Showcase Event. PharmStars members worked extensively with each startup to help shape their pitch to best communicate their value proposition and proposed partnership arrangements in the most effective way. 

At the PharmStars’ mentoring sessions, the PharmStars team provided guidance to the SmartTab team on communicating their solution in the most powerful way possible. This preparation was extremely valuable and was put to use at the Showcase Event in Boston, MA where the participating Pharma members met the startups for the first time.

Sacha2 (1)

Photo courtesy of PharmStars

The PharmStars Showcase in Boston

We arrived at the Showcase Event and met our fellow startup participants from the cohort in-person for the first time. The welcome dinner was an opportunity for the founders to reminisce about the weekly zoom classes over the previous 10 weeks. Many of the startup executives flew in from around the world to participate.

The PharmStars team did a great job preparing everything leading up to the event—from the event location and hotels, to the meeting spaces—everything was planned and implemented beautifully. The whole showcase experience from start to finish was a week to remember. The building of what will hopefully be lasting relationships between startups and pharmaceutical companies has the potential to bring exciting new innovative digital solutions to patients. 

Bob2 (1)

Photo courtesy of PharmStars

The next morning was the long-awaited pitch presentations to pharma. The 12 startups all pitched one after another, short presentations with Q+A for each. There was a distinct energy in the room, to have such cutting-edge innovative companies all together pitching under one roof. You could sense that history was being made and a new path was being forged by the PharmStars program.  

Robert Niichel led SmartTab’s presentation to share the digital drug delivery revolution. He shared about each application in the SmartTab platform and the significant progress the company has made and the roadmap to commercialization. Most importantly, he created an opportunity for attending Pharma companies to partner with SmartTab in clinical trials to develop novel therapies for their therapeutic areas.

Group (1)

Photo courtesy of PharmStars

CapsuleHold (1)

Photo courtesy of PharmStars

The Pharma members and startups were impressed and intrigued by the presentation. One participant said that the energy in the room shifted after Robert’s presentation. You could see the excitement when Robert pulled out the capsule prototypes and shared them with participants during the break.

Completion (1)

Photo courtesy of PharmStars

Upon completion of the presentation the startups and pharmaceutical member companies were presented certificates and acknowledged for their journey through PharmStars. The PharmStars team made it fun and celebrated both the startups and pharma members.

First cohort of digital health startups graduates from PharmStars accelerator

At the meetings over the next two days was when the partnering conversations really ramped up. SmartTab and the 11 other companies had pre-scheduled meetings with the Pharma members, coordinated by PharmStars to discuss potential partnering. Each meeting included executives of the pharmaceutical member companies and the relevant teams.

The meetings were productive and got down to business immediately. Compared to our past initial meetings with Pharma which were more introductory in nature, these meetings were transformative. We began discussing details around potential partnerships and what the next steps would be. Now, we are expecting to have follow up meetings in the coming days and months.

Ultimately, PharmStars provided education and connections that lead to more meaningful discussions between Startups and Pharma. This is the beginning of a new era of collaboration. We will take our PharmStars education with us every step of the way as we continue the journey of advancing our novel drug delivery platform.

ShowcasingCapsule (1)

Photo courtesy of PharmStars

CapsuleBox (1)

Photo courtesy of PharmStars

The relationships created through PharmStars are remarkably valuable. Although we have graduated, we will continue to be associated with PharmStars and look forward to staying in touch as we continue the development of the SmartTab platform.

Read More

When Wireless Technology Meets Drug Delivery with Robert Niichel, CEO of SmartTab

8 months ago

Impetus Digital‘s Fireside Chat, features a conversation with Robert Niichel, Founder/CEO of SmartTab. This webinar and podcast explored the concept of personalized wireless drug delivery, including its advantages, barriers, and current status. They also discussed the future of drug medicine, the Internet of Medical Things, AI, and much more! 

Listen on Apple Podcasts , Spotify , or watch the conversation on video below: 



$100,000+ in Committed Investments and Announcing the PharmStars Accelerator

8 months ago

We are excited to report that in the first few week of our equity crowdfunding campaign on StartEngine we passed the $100,000 mark in committed investments.  Thank you to our investors and welcome to the SmartTab community!  Your investment will support our mission to advance SmartTab’s wireless ingestible technology for targeted, oral delivery of biologics and other medications. To provide novel, effective therapies that take the guesswork out of compliance while simultaneously improving patient quality of life.


We’re also pleased to announce SmartTab has joined the PharmStars accelerator and showcase in Boston to develop partnerships with top pharmaceutical companies. SmartTab’s CEO, Robert Niichel, and Chief Marketing Officer, Sacha Francois Heppell, presented to a group of digital health pharmaceutical executives that followed a series of productive meetings to explore the path of commercializing SmartTab’s platform for their pharmaceutical therapies.

Follow this link for to the MedCity News article and stay tuned for more exciting news. 

SmartTab Announces Participation in First Pharma-Focused Accelerator for Digital Health Partnerships

8 months ago

Press Release

PharmStars Announces 2021 Accelerator Graduates


12 digital health startups have successfully completed PharmStars’ inaugural 10-week pharma-focused accelerator program.


Boston, MA, December 08, 2021 --(PR.com)-- PharmStars, the pharma-focused accelerator for digital health startups, is delighted to announce the graduation of 12 startups from its fall 2021 inaugural program. The graduates successfully completed a 10-week accelerator program, which culminated at the Showcase Event on November 17-19 in Boston.

The Showcase Event brought together the participating startups and PharmStars’ innovation-minded pharma members. PharmStars’ six members include Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, Sumitovant Biopharma, and others.

PharmStars focuses on bridging the “pharma-startup gap” by helping pharma and startups overcome partnership barriers. PharmStars’ unique PharmaU program provides education and mentorship that helps startups and pharma partner more effectively.

The first cohort was selected in September 2021 following a competitive application process. Each startup offers a novel digital health solution related to the theme “Innovations in Clinical Trials.” Their products represent a diverse array of digital health solutions, including digital biomarkers, patient engagement tools, clinical trial recruitment tools, novel drug delivery mechanisms, real-world evidence (RWE) collection capabilities, and data analysis tools.

At the Showcase Event, startups pitched pharma companies on their solutions and engaged with pharma representatives in one-on-one meetings. Participating startups said that the Showcase Event was extremely successful and positive. “Not just one, but all of our meetings over the past two days have been the most productive of any meetings in the five-year history of our company,” said the CEO of one of the startups.

The CEO of another participating startup said, “PharmStars is truly a game changer for the industry and is helping accelerate the digital transformation of pharmaceutical companies. We are proud to be part of the first-ever PharmStars cohort.”

The following 12 digital health startups have successfully completed the PharmStars accelerator:

· Droice Labs (New York, NY): Data harmonization and real-world evidence generation from electronic medical records and other unstructured data sources.

· EVOCAL Health (Hamburg, Germany): Vocal biomarker platform for continuous data capture and monitoring of patients with respiratory and cardiovascular disease.

· Liyfe (New York, NY): AI-based digital nurse chatbot for patient engagement and capture of RWE in oncology and nonalcoholic steatohepatitis (NASH).

· Longenesis (Riga, Latvia): Clinical trial participant identification and engagement platform for efficient trial preparation and enrollment.

· Neucruit (London, England): Leveraging social media platforms to recruit clinical trial participants.

· Nori Health (Amsterdam, Netherlands): Digital therapy app for management of, and capture of real-world evidence from, patients with Inflammatory Bowel Disease (IBD).

· nQ Medical (Cambridge, MA): Passive, personal device-based digital biomarker for cognitive and motor disorders.

· Prism Analytic Technologies (Cambridge, MA): Data analytics and visualization platform for selection and optimization of clinical trial endpoints and trial design components for any disease indication.

· Seascape Clinical (Redwood City, CA): Clinical operations platform that eliminates repetitive manual tasks and context switching, enabling faster trial performance insights and more efficient team collaboration.

· SmartTab (Denver, CO): Novel ingestible drug delivery platform for targeted, oral delivery of biologics and other medications.

· Tag.bio (San Francisco, CA): Data mesh platform to harmonize siloed data sources with an analytics layer, enabling data-driven decision-making in drug development.

· The Clinician (Auckland, New Zealand): Bi-directional patient communication and engagement platform to improve the effectiveness of decentralized clinical trials.


Read the full press release... 


About PharmStars

PharmStars is the member-based, pharma-focused accelerator for digital health startups. Through our extensive expertise across pharma, startups, digital health, and innovation, we understand the challenges that pharma and startups face when seeking to collaborate. Our PharmaU program supports digital health startups and our pharma members in “bridging the gap,” leading to greater success and faster adoption of “beyond the molecule” solutions for patients.



SmartTab Added to the Top 100 Digital Health Companies List

8 months ago

The Medical Futurist has added SmartTab to the TOP100 Digital Health Companies List. 

Dr. Bertalan is one of the few people who is monitoring the digital health ecosystem closely and has curated a list that brings the Top 100 companies together to paint a picture of the future of digital health. His selection criteria is based on discussions they have across the digital health landscape.



SmartTab is proud to be featured as one of The Medical Futurist’s Top 100 Digital Health Companies, alongside innovative companies in the digital healthcare space Pilleve, AdhereTech and EtectRX. The Medical Futurist is a highly successful platform that shows how digital technologies, artificial intelligence and innovation shapes the future of healthcare with thousands of subscribers around the world.  

Developing Accuracy in Treatments and Diagnosis Powered by Capsules and Wireless Technology

9 months ago

Our Chief Technology Officer, Douglas Miller, PhD joins the Medstreet Journal podcast to talk about the innovations we are working on in the health tech industry and how Wireless Technology meets Drug Delivery with SmartTab. He explains what our team is working on every day and what our priorities are at SmartTab as a company. Doug shares about the multi-dose platform and how we’re currently working in developing a system where the need to take multiple pills per day decreases and compliance goes up. How wireless technology plays a critical role in the accuracy and efficacy of diagnosis and treatments of various diseases especially cancer and other critical conditions. More here: https://blog.smarttab.co/developing-more-accuracy-in-treatments-and-diagnosis




Show More Updates End of Updates

Comments ({{profileCtrl.startup.comments_count}} total)

{{profileCtrl.newComment.body.length}}/2500
Please sign in to post a comment.
Please use Updates for communications.
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}